Compare HALO & CSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HALO | CSL |
|---|---|---|
| Founded | 1998 | 1917 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 13.3B |
| IPO Year | 2001 | 1994 |
| Metric | HALO | CSL |
|---|---|---|
| Price | $100.98 | $392.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $119.89 | ★ $401.88 |
| AVG Volume (30 Days) | ★ 2.3M | 374.0K |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 1.26% |
| EPS Growth | ★ N/A | N/A |
| EPS | 5.12 | ★ 14.60 |
| Revenue | $151,862,000.00 | ★ $5,003,600,000.00 |
| Revenue This Year | $35.97 | $5.76 |
| Revenue Next Year | $14.85 | $5.25 |
| P/E Ratio | ★ $19.84 | $27.27 |
| Revenue Growth | N/A | ★ 9.08 |
| 52 Week Low | $61.23 | $293.43 |
| 52 Week High | $134.00 | $432.91 |
| Indicator | HALO | CSL |
|---|---|---|
| Relative Strength Index (RSI) | 27.51 | 64.46 |
| Support Level | $64.08 | $320.15 |
| Resistance Level | $111.15 | $398.79 |
| Average True Range (ATR) | 4.64 | 14.03 |
| MACD | -3.78 | 2.38 |
| Stochastic Oscillator | 6.04 | 76.55 |
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Carlisle Companies Inc is a holding company that manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. It operates through two segments: Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The majority of revenue comes from Carlisle Construction Materials, and more than half of total revenue is earned in the United States. Carlisle Construction Materials produces premium single-ply roofing products and warranted roof systems, including EPDM, TPO, PVC membrane, and polyiso insulation. Carlisle Weatherproofing Technologies produces building envelope solutions, including waterproofing, moisture protection products, air/vapor barriers, and spray polyurethane foam systems.